DCVC Announcements
First Investment: 2016
A stem cell transplant from a compatible donor is often the best hope for patients with leukemia and other cancers. But these treatments often come with long-lasting and even fatal side effects, such as graft-versus-host disease (GvHD). Orca Bio lowers the risk of GvHD by identifying the donor cells with real therapeutic benefits and screening out the rest, providing transplant recipients with a designer immune system.
News & Insights
Explore Companies
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery